Your cart

Blood Transfusion and Apheresis: Impact on Ionized Magnesium and Ionized Calcium

Blood gas Webinar Logo
Blood Transfusion and Apheresis:
Impact on Ionized Magnesium and Ionized Calcium
Blood transfusion and apheresis protocols can be life-saving for critically ill patients by removing toxins, medications, destructive antibodies, or clotting factors from peripheral blood. However, blood levels of ionized magnesium (iMg) may drop as much as 60% at the end of an apheresis procedure. In addition, citrate used as an anticoagulant will bind with calcium, inducing hypocalcemia in many cases. In the current presentation, Dr. Sanford will discuss concerns around apheresis and transfusion procedures including the symptoms observed when magnesium or calcium are depleted and the effects of supplementation. She will also review the factors in different patient populations that influence the type of replacement fluid chosen, the necessity to monitor both iMg and iCa in these patients, and the importance of supplementing according to their ionized levels.



Primary Speaker:
Dr. Kimberly Sanford, MD.
Professor of Pathology, Medical Director of Transfusion Medicine – VCU Health

The importance of measuring ionized magnesium
in critically ill patients
Hypomagnesemia (low levels of magnesium) is associated with several clinical conditions, ranging from cardiovascular disease to transplantation and sepsis. Traditionally, total magnesium (tMg) measured in the laboratory is used to identify patients with hypomagnesemia. However, various studies have shown the clinical significance of using iMg, the biologically active form of magnesium, to correctly identify patients with hypomagnesemia. Dr. Naveen Bangia will review the clinical literature around the utility of measuring iMg in various clinical settings.

Dr. Danilo Pardo



Speaker:

Naveen Bangia, PhD
Director, Medical and Scientific Affairs Nova Biomedical

Learning Objectives:
  • • Understand the different patient-specific indications for plasmapheresis
  • • Describe the changes in divalent cations calcium and magnesium and learn how to monitor these changes through appropriate testing and symptom identification
  • • Explain the additional adverse events that may occur during apheresis
Dates and Times:
Thursday, June 12, 1 pm Eastern Time
Thursday, June 26, 10 am Eastern Time
Time:
6PM ET / 7PM GMT-3
Duration:
1 Hour
This program offers 1 hour of P.A.C.E. continuing education credits. Nova Biomedical is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. This program has been approved by the American Association of Critical-Care Nurses (AACN), for 1.00 CERPs, Synergy CERP Category A, File Number 00000. Approval refers to recognition of continuing education only and does not imply AACN approval or endorsement of the content of this educational activity or the products mentioned.

Clinical Significance of Ionized Magnesium in Critical Care

Blood gas Webinar Logo
Clinical Significance of Ionized Magnesium in Critical Care
Blood gas analyzers are essential devices in point-of-care settings such as respiratory care units, surgical suites, intensive care units, emergency rooms, and the central lab. An advanced menu of tests that includes glucose, lactate, ionized calcium, ionized magnesium, electrolytes, estimated plasma volume, BUN and creatinine along with blood gas provides important results at the point of care. This presentation will discuss the clinical value of having access to an advanced complement of blood test results and the significance of ionized magnesium results in critically ill patients.

Presenter

 

Presenter: Jessica Colon-Franco, PhD
Section Head, Clinical Biochemistry Medical Director,
Special Chemistry Department of Laboratory Medicine
Cleveland Clinic

Presenter



Presenter:
Marcin Pacek
Medical and Scientific Affairs Director
Nova Biomedical

Date:
April 10 & April 24
TIme:
1PM EST / 3pm EST
Duration:
1 Hour

Clinical Utility of Ionised Magnesium for Patients in Critical Care

Blood gas Webinar Logo
Clinical Utility of Ionised Magnesium for Patients in Critical Care
Magnesium, the second most abundant cation in our body and cofactor for over 600 enzymes. It is involved in controlling various important physiological processes such as antiarrhythmic action, vascular tone action, muscle contraction, glucose metabolism and insulin homeostasis. Monitoring blood magnesium levels is usually done by the total magnesium (tMg); however, the physiologically active fraction of the magnesium is the 'ionised magnesium (iMg).'

In this session, Dr Masaru Yamamoto will uncover the key differences between iMg and tMg, review literature on monitoring methods, and their impact on patient outcomes. Leveraging his extensive experience in clinical chemistry and medical affairs, and his distinguished background at Nova Biomedical, Dr Yamamoto will provide valuable insights into the latest research and its clinical implications.

Presenter

Presenter 1:

Dr Masaru Yamamoto Ph.D.
Director, Asia Pacific, Medical & Scientific Affairs (MASA)
Nova Biomedical

Presenter

Presenter 2:

Steve Mawditt (Moderator)
National Sales Manager ANZ Nova Biomedical

Date:
6 March 2025
TIme:
Sydney/Melbourne: 5.30PM
Brisbane: 4.30PM
Adelaide: 5.00PM
Perth: 2.30PM
Auckland, NZ: 7.30PM
Duration:
1 Hour
Blood gas Webinar Logo
Clinical Utility of Ionised Magnesium for Patients in Critical Care
Magnesium, the second most abundant cation in our body and cofactor for over 600 enzymes. It is involved in controlling various important physiological processes such as antiarrhythmic action, vascular tone action, muscle contraction, glucose metabolism and insulin homeostasis. Monitoring blood magnesium levels is usually done by the total magnesium (tMg); however, the physiologically active fraction of the magnesium is the 'ionised magnesium (iMg).'

In this session, Dr Masaru Yamamoto will uncover the key differences between iMg and tMg, review literature on monitoring methods, and their impact on patient outcomes. Leveraging his extensive experience in clinical chemistry and medical affairs, and his distinguished background at Nova Biomedical, Dr Yamamoto will provide valuable insights into the latest research and its clinical implications.
Presenter
Presenter 1:

Dr Masaru Yamamoto Ph.D.
Director, Asia Pacific, Medical & Scientific Affairs (MASA)
Nova Biomedical

Presenter
Presenter 2:

Steve Mawditt
(Moderator) National Sales Manager ANZ
Nova Biomedical

Date:
6 February 2025
TIme:
Sydney/Melbourne: 7.00PM
Brisbane: 6.00PM
Adelaide: 6.30PM
Perth: 4.00PM
Auckland, NZ: 9.00PM
Duration:
1 Hour